Literature DB >> 23998997

Validation of next-generation sequencing technologies in genetic diagnosis of dementia.

John Beck1, Alan Pittman, Gary Adamson, Tracy Campbell, Joanna Kenny, Henry Houlden, Jon D Rohrer, Rohan de Silva, Maryam Shoai, James Uphill, Mark Poulter, John Hardy, Catherine J Mummery, Jason D Warren, Jonathan M Schott, Nick C Fox, Martin N Rossor, John Collinge, Simon Mead.   

Abstract

Identification of a specific genetic cause of early onset dementia (EOD) is important but can be difficult because of pleiotropy, locus heterogeneity and accessibility of gene tests. Here we assess the use of next generation sequencing (NGS) technologies as a quick, accurate and cost effective method to determine genetic diagnosis in EOD. We developed gene panel based technologies to assess 16 genes known to harbour mutations causal of dementia and combined these with PCR based assessments of the C9orf72 hexanucleotide repeat expansion and the octapeptide repeat region of PRNP. In a blinded study of 95 samples we show very high sensitivity and specificity are achievable using either Ion Torrent or MiSeq sequencing platforms. Modifications to the gene panel permit accurate detection of structural variation in APP. In 2/10 samples which had been selected because they possess a variant of uncertain significance the new technology discovered a causal mutation in genes not previously sequenced. A large proportion (23/85) of samples showed genetic variants of uncertain significance in addition to known mutations. The MRC Dementia Gene Panel and similar technologies are likely to be transformational in EOD diagnosis with a significant impact on the proportion of patients in whom a genetic cause is identified.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dementia; Diagnosis; Genetic; Ion torrent; MiSeq; NGS; Neurogenetics; Next-generation sequencing; Sequencing

Mesh:

Substances:

Year:  2013        PMID: 23998997     DOI: 10.1016/j.neurobiolaging.2013.07.017

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  30 in total

1.  SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease.

Authors:  G Nicolas; C Charbonnier; D Wallon; O Quenez; C Bellenguez; B Grenier-Boley; S Rousseau; A-C Richard; A Rovelet-Lecrux; K Le Guennec; D Bacq; J-G Garnier; R Olaso; A Boland; V Meyer; J-F Deleuze; P Amouyel; H M Munter; G Bourque; M Lathrop; T Frebourg; R Redon; L Letenneur; J-F Dartigues; E Génin; J-C Lambert; D Hannequin; D Campion
Journal:  Mol Psychiatry       Date:  2015-08-25       Impact factor: 15.992

2.  Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons.

Authors:  Gaël Nicolas; David Wallon; Camille Charbonnier; Olivier Quenez; Stéphane Rousseau; Anne-Claire Richard; Anne Rovelet-Lecrux; Sophie Coutant; Kilan Le Guennec; Delphine Bacq; Jean-Guillaume Garnier; Robert Olaso; Anne Boland; Vincent Meyer; Jean-François Deleuze; Hans Markus Munter; Guillaume Bourque; Daniel Auld; Alexandre Montpetit; Mark Lathrop; Lucie Guyant-Maréchal; Olivier Martinaud; Jérémie Pariente; Adeline Rollin-Sillaire; Florence Pasquier; Isabelle Le Ber; Marie Sarazin; Bernard Croisile; Claire Boutoleau-Bretonnière; Catherine Thomas-Antérion; Claire Paquet; Mathilde Sauvée; Olivier Moreaud; Audrey Gabelle; François Sellal; Mathieu Ceccaldi; Ludivine Chamard; Frédéric Blanc; Thierry Frebourg; Dominique Campion; Didier Hannequin
Journal:  Eur J Hum Genet       Date:  2015-08-05       Impact factor: 4.246

3.  Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy.

Authors:  Zane Jaunmuktane; Simon Mead; Matthew Ellis; Jonathan D F Wadsworth; Andrew J Nicoll; Joanna Kenny; Francesca Launchbury; Jacqueline Linehan; Angela Richard-Loendt; A Sarah Walker; Peter Rudge; John Collinge; Sebastian Brandner
Journal:  Nature       Date:  2015-09-10       Impact factor: 49.962

Review 4.  Next generation sequencing and the future of genetic diagnosis.

Authors:  Katja Lohmann; Christine Klein
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

5.  Multiple variants in families with amyotrophic lateral sclerosis and frontotemporal dementia related to C9orf72 repeat expansion: further observations on their oligogenic nature.

Authors:  Maria Pia Giannoccaro; Anna Bartoletti-Stella; Silvia Piras; Annalisa Pession; Patrizia De Massis; Federico Oppi; Michelangelo Stanzani-Maserati; Elena Pasini; Simone Baiardi; Patrizia Avoni; Piero Parchi; Rocco Liguori; Sabina Capellari
Journal:  J Neurol       Date:  2017-06-15       Impact factor: 4.849

Review 6.  Genetic prion disease: Experience of a rapidly progressive dementia center in the United States and a review of the literature.

Authors:  Leonel T Takada; Mee-Ohk Kim; Ross W Cleveland; Katherine Wong; Sven A Forner; Ignacio Illán Gala; Jamie C Fong; Michael D Geschwind
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-01       Impact factor: 3.568

Review 7.  A new prion disease: relationship with central and peripheral amyloidoses.

Authors:  Simon Mead; Mary M Reilly
Journal:  Nat Rev Neurol       Date:  2015-01-27       Impact factor: 42.937

Review 8.  Genetic testing in dementia - utility and clinical strategies.

Authors:  Carolin A M Koriath; Joanna Kenny; Natalie S Ryan; Jonathan D Rohrer; Jonathan M Schott; Henry Houlden; Nick C Fox; Sarah J Tabrizi; Simon Mead
Journal:  Nat Rev Neurol       Date:  2020-11-09       Impact factor: 42.937

Review 9.  Clinical, biological, and imaging features of monogenic Alzheimer's Disease.

Authors:  Andrea Pilotto; Alessandro Padovani; Barbara Borroni
Journal:  Biomed Res Int       Date:  2013-11-27       Impact factor: 3.411

10.  Alzheimer's disease neuropathological change three decades after iatrogenic amyloid-β transmission.

Authors:  Zane Jaunmuktane; Gargi Banerjee; Simon Paine; Adrian Parry-Jones; Peter Rudge; Joan Grieve; Ahmed K Toma; Simon F Farmer; Simon Mead; Henry Houlden; David J Werring; Sebastian Brandner
Journal:  Acta Neuropathol       Date:  2021-05-28       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.